Phase Ib study of dabrafenib, trametinib, irinotecan and cetuximab in BRAF V600Emutated metastatic colorectal cancer.

被引：0
|
作者：
Chen, Yungchang
Li, Xiaoqian
Man Yuxin
Hu, Hai
Wang, Liyang
Zhang, Zhixuan
Chen, Ping
Liu, Yang
Lu, Jin
Lin, Tongyu
机构：
[1] Univ Elect Sci & Technol China, Sch Med, Sichuan Canc Ctr, Sichuan Canc Hosp & Inst, Chengdu, Peoples R China
[2] Shandong Acad Med Sci, Shandong Canc Hosp, Dept Med Oncol, Jinan 250117, Peoples R China
[3] Univ Elect Sci & Technol China, Sch Med, Sichuan Canc Ctr, Dept Pathol,Sichuan Canc Hosp & Inst, Chengdu, Sichuan, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
156
引用
收藏
页码：156 / 156
页数：1
相关论文
共 50 条
  • [1] A phase ib-II study of dabrafenib, trametinib, cetuximab plus irinotecan in patients with BRAF mutant metastatic colorectal cancer: Subgroup analysis and biomarker identification
    Chen, Yungchang
    Hu, Hai
    Song, Bo
    Shang, Jin
    Man, Yuxin
    Guo, Qian
    Yuan, Hongfan
    Rui, Yuanyi
    Deng, Zijian
    Pan, Tao
    Yi, Bo
    Zhang, Zhixuan
    Chen, Ping
    Lu, Jin
    Zhong, Deyuan
    Lin, Tongyu
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [2] Combined BRAF and MEK Inhibition with Dabrafenib and Trametinib in BRAF V600-mutant colorectal cancer
    Loir, E.
    Cochereau, D.
    [J]. ONCOLOGIE, 2016, 18 (9-10) : 565 - 566
  • [3] Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer
    Corcoran, Ryan B.
    Atreya, Chloe E.
    Falchook, Gerald S.
    Kwak, Eunice L.
    Ryan, David P.
    Bendell, Johanna C.
    Hamid, Omid
    Messersmith, Wells A.
    Daud, Adil
    Kurzrock, Razelle
    Pierobon, Mariaelena
    Sun, Peng
    Cunningham, Elizabeth
    Little, Shonda
    Orford, Keith
    Motwani, Monica
    Bai, Yuchen
    Patel, Kiran
    Venook, Alan P.
    Kopetz, Scott
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (34) : 4023 - +
  • [4] Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC
    Planchard, David
    Besse, Benjamin
    Groen, Harry J. M.
    Hashemi, Sayed M. S.
    Mazieres, Julien
    Kim, Tae Min
    Quoix, Elisabeth
    Souquet, Pierre-Jean
    Barlesi, Fabrice
    Baik, Christina
    Villaruz, Liza C.
    Kelly, Ronan J.
    Zhang, Shirong
    Tan, Monique
    Gasal, Eduard
    Santarpia, Libero
    Johnson, Bruce E.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (01) : 103 - 115
  • [5] Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation
    Hong, David S.
    Morris, Van K.
    El Osta, Badi
    Sorokin, Alexey V.
    Janku, Filip
    Fu, Siqing
    Overman, Michael J.
    Piha-Paul, Sarina
    Subbiah, Vivek
    Kee, Bryan
    Tsimberidou, Apostolia M.
    Fogelman, David
    Bellido, Jorge
    Shureiqi, Imad
    Huang, Helen
    Atkins, Johnique
    Tarcic, Gabi
    Sommer, Nicolas
    Lanman, Richard
    Meric-Bernstam, Funda
    Kopetz, Scott
    [J]. CANCER DISCOVERY, 2016, 6 (12) : 1352 - 1365
  • [6] Phase Ib study of vemurafenib in combination with irinotecan and cetuximab in patients with BRAF-mutated metastatic colorectal cancer and advanced cancers.
    Hong, David S.
    Morris, Van Karlyle
    El Osta, Badi Edmond
    Fu, Siqing
    Overman, Michael J.
    Piha-Paul, Sarina Anne
    Subbiah, Vivek
    Kee, Bryan K.
    Tsimberidou, Apostolia Maria
    Zinner, Ralph
    Fogelman, David R.
    Bellido, Jorge
    Shureiqi, Imad
    Meric-Bernstam, Funda
    Kopetz, Scott
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [7] Phase IB study of the Src inhibitor dasatinib with FOLFOX and cetuximab in metastatic colorectal cancer.
    Lieu, C. H.
    Wolff, R. A.
    Eng, C.
    Overman, M. J.
    Henry, L.
    Coulson, R.
    Garrett, C. R.
    Abbruzzese, J. L.
    Gallick, G. E.
    Kopetz, S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [8] Response of metastatic melanoma with a rare BRAF V600K mutation to dabrafenib and trametinib
    Kromer, Christian
    Vlahova, Lyubomira D.
    Julius, Katharina
    Schnabel, Viktor
    Schoen, Michael P.
    Reuter-Jessen, Kirsten
    Seif Amir Hosseini, Ali
    Kretschmer, Lutz
    [J]. MELANOMA RESEARCH, 2022, 32 (02) : 124 - 127
  • [9] Encorafenib and cetuximab versus irinotecan/cetuximab or FOLFIRI/cetuximab in Chinese patients with BRAF V600E mutant metastatic colorectal cancer: The NAUTICAL CRC study.
    Wang, Xicheng
    Deng, Yanhong
    Zhang, Yanqiao
    Liu, Tianshu
    Yuan, Xianglin
    Yang, Jianwei
    Zhang, Tao
    Zang, Ai-min
    Liu, Yu
    Huang, Li
    Ye, Feng
    Zong, Hong
    Ba, Yi
    Klauck, Isabelle
    Vedovato, Jean-Claude
    Groc, Melanie
    Guo, Angela
    Shen, Lin
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (17_SUPPL) : LBA3559 - LBA3559
  • [10] Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer
    Subbiah, Vivek
    Kreitman, Robert J.
    Wainberg, Zev A.
    Cho, Jae Yong
    Schellens, Jan H. M.
    Soria, Jean Charles
    Wen, Patrick Y.
    Zielinski, Christoph
    Cabanillas, Maria E.
    Urbanowitz, Gladys
    Mookerjee, Bijoyesh
    Wang, Dazhe
    Rangwala, Fatima
    Keam, Bhumsuk
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (01) : 7 - +
12345